Press coverage about K2M Group (NASDAQ:KTWO) has trended positive recently, according to Accern. The research group ranks the sentiment of press coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. K2M Group earned a coverage optimism score of 0.36 on Accern’s scale. Accern also gave news coverage about the medical device company an impact score of 47.1233411089662 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
A number of equities analysts have recently commented on the stock. BidaskClub upgraded shares of K2M Group from a “hold” rating to a “buy” rating in a research report on Wednesday, March 7th. Oppenheimer set a $24.00 price objective on shares of K2M Group and gave the company a “buy” rating in a research report on Thursday, March 1st. Zacks Investment Research upgraded shares of K2M Group from a “sell” rating to a “hold” rating in a research report on Thursday, January 25th. Barclays restated a “buy” rating and issued a $25.00 price objective on shares of K2M Group in a research report on Tuesday, January 9th. Finally, Needham & Company LLC raised their price objective on shares of K2M Group from $20.00 to $23.00 and gave the company a “buy” rating in a research report on Tuesday, January 9th. One research analyst has rated the stock with a sell rating, two have given a hold rating and ten have issued a buy rating to the company. K2M Group presently has a consensus rating of “Buy” and a consensus price target of $24.50.
Shares of K2M Group (KTWO) opened at $19.60 on Tuesday. K2M Group has a 1 year low of $16.44 and a 1 year high of $25.99. The stock has a market cap of $854.31, a P/E ratio of -22.53 and a beta of 1.42. The company has a debt-to-equity ratio of 0.30, a quick ratio of 1.52 and a current ratio of 2.84.
About K2M Group
K2M Group Holdings, Inc is a medical device company focused on designing, developing and commercializing spine and minimally invasive technologies and techniques. The Company’s solutions are focused on achieving three-dimensional Total Body Balance. Its spine products are used by spine surgeons to treat spinal pathologies, such as deformity (primarily scoliosis), trauma and tumor.
Receive News & Ratings for K2M Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for K2M Group and related companies with MarketBeat.com's FREE daily email newsletter.